Long‐Term Outcomes and Toxicities in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens
Long-term responders showed favorable survival outcomes, with most maintaining disease control with local therapies even after progression. This held true regardless of treatment duration, PD-L1 TPS, or treatment line. Endocrinopathies were common long-term toxicities.
Authors
- Venessa Chin (ORCID: https://orcid.org/0000-0002-4630-4451)
- Inês Pires da Silva (ORCID: https://orcid.org/0000-0003-3540-8906)
- Lauren Brown (ORCID: https://orcid.org/0000-0002-9340-8392)
- Adnan Nagrial (ORCID: https://orcid.org/0000-0003-0275-2479)
- Bo Gao (ORCID: https://orcid.org/0000-0002-7881-6603)
- M. Maddula (ORCID: https://orcid.org/0009-0003-4819-9397)
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Melanoma Institute Australia (AU)
- Westmead Institute for Medical Research (AU)
- The Kinghorn Cancer Centre (AU)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/cnr2.70361
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00